Radiopharm Theranostics (RADX) Competitors $5.75 +0.15 (+2.68%) As of 09/5/2025 03:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsOwnershipSEC FilingsTrendsBuy This Stock RADX vs. CLYM, BDTX, MCRB, NVCT, SGMO, KYTX, GLSI, ELDN, CTOR, and MISTShould you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Climb Bio (CLYM), Black Diamond Therapeutics (BDTX), Seres Therapeutics (MCRB), Nuvectis Pharma (NVCT), Sangamo Therapeutics (SGMO), Kyverna Therapeutics (KYTX), Greenwich LifeSciences (GLSI), Eledon Pharmaceuticals (ELDN), Citius Oncology (CTOR), and Milestone Pharmaceuticals (MIST). These companies are all part of the "med - biomed/gene" industry. Radiopharm Theranostics vs. Its Competitors Climb Bio Black Diamond Therapeutics Seres Therapeutics Nuvectis Pharma Sangamo Therapeutics Kyverna Therapeutics Greenwich LifeSciences Eledon Pharmaceuticals Citius Oncology Milestone Pharmaceuticals Radiopharm Theranostics (NASDAQ:RADX) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations. Do insiders and institutionals believe in RADX or CLYM? 69.8% of Climb Bio shares are owned by institutional investors. 0.8% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, RADX or CLYM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadiopharm TheranosticsN/AN/AN/AN/AN/AClimb BioN/AN/A-$73.90M-$0.70-3.41 Does the media favor RADX or CLYM? In the previous week, Climb Bio had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 5 mentions for Climb Bio and 1 mentions for Radiopharm Theranostics. Climb Bio's average media sentiment score of 1.01 beat Radiopharm Theranostics' score of -1.00 indicating that Climb Bio is being referred to more favorably in the news media. Company Overall Sentiment Radiopharm Theranostics Negative Climb Bio Positive Do analysts recommend RADX or CLYM? Radiopharm Theranostics presently has a consensus target price of $15.00, indicating a potential upside of 160.87%. Climb Bio has a consensus target price of $9.00, indicating a potential upside of 276.57%. Given Climb Bio's higher probable upside, analysts clearly believe Climb Bio is more favorable than Radiopharm Theranostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Radiopharm Theranostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Climb Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Is RADX or CLYM more profitable? Radiopharm Theranostics' return on equity of 0.00% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets Radiopharm TheranosticsN/A N/A N/A Climb Bio N/A -23.10%-22.47% SummaryClimb Bio beats Radiopharm Theranostics on 6 of the 9 factors compared between the two stocks. Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RADX vs. The Competition Export to ExcelMetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.33M$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E RatioN/A21.1076.1526.11Price / SalesN/A466.44562.61123.62Price / CashN/A45.7236.9959.28Price / BookN/A9.8711.486.09Net IncomeN/A-$53.42M$3.29B$266.51M7 Day Performance4.74%2.93%1.27%0.46%1 Month Performance13.86%9.85%7.94%4.59%1 Year PerformanceN/A15.74%62.94%26.04% Radiopharm Theranostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RADXRadiopharm TheranosticsN/A$5.75+2.7%$15.00+160.9%N/A$45.33MN/A0.00N/ANegative NewsAnalyst RevisionCLYMClimb Bio3.4068 of 5 stars$2.33-4.5%$9.00+286.3%N/A$165.34MN/A-3.339News CoveragePositive NewsGap UpBDTXBlack Diamond Therapeutics3.442 of 5 stars$2.87-0.3%$11.67+306.5%-47.3%$163.97MN/A12.4890News CoveragePositive NewsAnalyst ForecastMCRBSeres Therapeutics3.0169 of 5 stars$18.80+1.6%$73.67+291.8%+7.6%$161.96M$126.32M-4.09330NVCTNuvectis Pharma3.2478 of 5 stars$6.52+2.7%$15.33+135.2%+8.4%$161.65MN/A-5.578News CoverageSGMOSangamo Therapeutics1.9269 of 5 stars$0.53-0.7%$4.50+749.1%-27.2%$161.11M$57.80M-1.83480News CoverageAnalyst ForecastKYTXKyverna Therapeutics2.7649 of 5 stars$3.63-2.4%$16.60+357.3%-48.0%$160.87M$7.03M-0.9996GLSIGreenwich LifeSciences1.1588 of 5 stars$10.97-4.9%$42.00+282.9%-18.2%$157.16MN/A-8.073ELDNEledon Pharmaceuticals2.01 of 5 stars$2.61+0.8%$10.00+283.1%+5.4%$155.09MN/A-2.2310News CoverageAnalyst ForecastAnalyst RevisionCTORCitius Oncology0.8754 of 5 stars$1.87-5.1%$3.00+60.4%+0.0%$154.39MN/A0.00N/AGap DownMISTMilestone Pharmaceuticals1.623 of 5 stars$1.78flat$5.00+180.9%+23.3%$151.29M$1M-2.1230Positive News Related Companies and Tools Related Companies CLYM Competitors BDTX Competitors MCRB Competitors NVCT Competitors SGMO Competitors KYTX Competitors GLSI Competitors ELDN Competitors CTOR Competitors MIST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RADX) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
